JP2024527576A5 - - Google Patents
Info
- Publication number
- JP2024527576A5 JP2024527576A5 JP2024500409A JP2024500409A JP2024527576A5 JP 2024527576 A5 JP2024527576 A5 JP 2024527576A5 JP 2024500409 A JP2024500409 A JP 2024500409A JP 2024500409 A JP2024500409 A JP 2024500409A JP 2024527576 A5 JP2024527576 A5 JP 2024527576A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- monoclonal antibody
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163219175P | 2021-07-07 | 2021-07-07 | |
| US63/219,175 | 2021-07-07 | ||
| PCT/IB2022/000409 WO2023281313A1 (en) | 2021-07-07 | 2022-07-06 | Anti-tnfr2 antibody and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527576A JP2024527576A (ja) | 2024-07-25 |
| JP2024527576A5 true JP2024527576A5 (cg-RX-API-DMAC7.html) | 2025-07-18 |
Family
ID=84800439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500409A Pending JP2024527576A (ja) | 2021-07-07 | 2022-07-06 | 抗tnfr2抗体及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4367140A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527576A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240032985A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117980336A (cg-RX-API-DMAC7.html) |
| AR (1) | AR126387A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022308421A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3224693A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202309096A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023281313A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL316894A (en) * | 2022-05-26 | 2025-01-01 | Pfizer | ANTI-TNFR2 ANTIBODIES AND METHODS OF USE THEREOF |
| WO2024233258A1 (en) * | 2023-05-05 | 2024-11-14 | Cureimmune Therapeutics Inc. | Anti-tnfr2 antibodies and uses thereof |
| WO2026119935A1 (en) | 2024-12-03 | 2026-06-11 | Resano Gmbh | Combination comprising a tumor necrosis factor receptor 2 agonist |
| WO2026119926A1 (en) | 2024-12-03 | 2026-06-11 | Resano Gmbh | Agonist polypeptide for use in treating and/or preventing heart failure |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017040312A1 (en) * | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| WO2019094559A2 (en) * | 2017-11-09 | 2019-05-16 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
| US20210371537A1 (en) * | 2018-09-18 | 2021-12-02 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
| CN113874083A (zh) * | 2019-03-01 | 2021-12-31 | 梅里麦克制药股份有限公司 | 抗-tnfr2抗体及其用途 |
| EP3907240A4 (en) * | 2019-08-02 | 2023-02-22 | Jiangsu Simcere Pharmaceutical Co., Ltd. | ANTI-TNFR2 ANTIBODIES AND USE THEREOF |
| AU2020348224A1 (en) * | 2019-09-17 | 2022-05-12 | Apexigen, Inc. | Anti-TNFR2 antibodies and methods of use |
| CN112480259B (zh) * | 2021-02-05 | 2021-05-04 | 百奥赛图(北京)医药科技股份有限公司 | 抗tnfr2抗体及其用途 |
-
2022
- 2022-07-06 JP JP2024500409A patent/JP2024527576A/ja active Pending
- 2022-07-06 AU AU2022308421A patent/AU2022308421A1/en active Pending
- 2022-07-06 CA CA3224693A patent/CA3224693A1/en active Pending
- 2022-07-06 EP EP22837100.1A patent/EP4367140A4/en not_active Withdrawn
- 2022-07-06 WO PCT/IB2022/000409 patent/WO2023281313A1/en not_active Ceased
- 2022-07-06 AR ARP220101767A patent/AR126387A1/es unknown
- 2022-07-06 TW TW111125395A patent/TW202309096A/zh unknown
- 2022-07-06 KR KR1020247004535A patent/KR20240032985A/ko active Pending
- 2022-07-06 CN CN202280060055.4A patent/CN117980336A/zh active Pending